NCCN Guidelines for Patients® | Myeloproliferative Neoplasms

66 NCCN Guidelines for Patients ® : Myeloproliferative Neoplasms, 2018 Acronyms Acronyms AML acute myeloid leukemia CBC complete blood count CML chronic myeloid leukemia CMV cytomegalovirus CT computed tomography DIPSS-PLUS Dynamic International Prognostic Scoring System-PLUS DNA deoxyribonucleic acid EPO erythropoietin ESA erythropoiesis-stimulating agent ET essential thrombocythemia FDA Food and Drug Administration FISH fluorescence in situ hybridization GVL graft-versus-leukemia HCT hematopoietic cell transplant HLAs human leukocyte antigens INT-1 intermediate-1 INT-2 intermediate-2 JAK Janus-associated kinase LDH lactate dehydrogenase LMWH low-molecular-weight heparin MDS myelodysplastic syndrome MF myelofibrosis MPN myeloproliferative neoplasm MPN-SAF Myeloproliferative Neoplasm Symptom Assessment Form MRI magnetic resonance imaging NCCN National Comprehensive Cancer Network PMF primary myelofibrosis prePMF prefibrotic PMF PV polycythemia vera QPCR quantitative reverse transcriptase-polymerase chain reaction TLS tumor lysis syndrome VWD von Willebrand disease

RkJQdWJsaXNoZXIy MTE3MTE1